NEW YORK – ImmunoScape said on Wednesday that it has raised $11 million in a funding round led by venture firm Anzu Partners.
The Singapore-based company will use the funds to expand its presence in the US market and to continue development and commercialization of its immune profiling platform, which uses mass cytometry to profile T-cell response in cancer and infectious disease.
ImmunoScape's focus is providing immune profiling to support development of cancer immunotherapies.